SynthesisBMC cardiovascular disorders2017
Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Tolvaptan for water retention in heart failure: a systematic review.Systematic reviews · 2023Pooled it
- Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.Clinical cardiology · 2022Pooled it
- Ultrafiltration for acute heart failure.The Cochrane database of systematic reviews · 2022Pooled it
- Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.The Journal of international medical research · 2019Pooled it
- Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials.BMJ open · 2019Pooled it
- Acute heart failure : An unmet medical need.Herz · 2019Pooled it
- Prognostic impact of the acute reactiveness to intravenous administration of tolvaptan sodium phosphate in patients with acute decompensated heart failure.European heart journal open · 2025Article
- Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.Current heart failure reports · 2025Review
- Potential amelioration of liver function by low-dose tolvaptan in heart failure patients.Toxicology reports · 2025Article
- Hypertension and Heart Failure: From Pathophysiology to Treatment.International journal of molecular sciences · 2024Review
- Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/II study.International journal of surgery protocols · 2024Article
- Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.ESC heart failure · 2021Article
- Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.Circulation research · 2021Review
- Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.BMC cardiovascular disorders · 2020Article
- Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.Heart and vessels · 2019Article
- Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial.Medicine · 2019Article
- Article
- Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis.Journal of clinical medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute heart failure, which requires urgent evaluation and treatment, is a leading cause for admission to the emergency department. The aim of this meta-analysis was to evaluate the effects of tolvaptan on acute heart failure and compare them with the effects of conventional therapy or placebo.
methodsThe electronic databases PubMed, EMBASE, and the Cochrane Controlled Trial registry were searched from their starting dates to October 24, 2016. Two authors independently read the trials and extracted related information from the included studies. We used fixed-effects or random-effects models to assess the overall combined risk estimates according to I
resultsSix randomised controlled trials from eight articles, with a total of 746 patients, were included for analysis. Compared with the control, tolvaptan reduced body weight in two days (WMD 1.35; 95% CI 0.75 to 1.96), elevated sodium level in two days (WMD 2.33; 95% CI 1.08 to 3.57) and five days (WMD 1.57; 95% CI 0.04 to 3.09), and ameliorated symptoms of dyspnoea (RR 0.82; 95% CI 0.71-0.95). However, tolvaptan did not improve long-term (RR 1.04; 95% CI 0.66-1.62) or short-term all-cause mortality (RR 0.89; 95% CI 0.45-1.76), incidence of clinical events (worsening heart failure, RR 0.75; 95% CI 0.50-1.12 and worsening renal function, RR 0.97; 95% CI 0.75-1.27), and length of hospital stay in patients (WMD 0.14; 95% CI -0.29 to 2.38) with acute heart failure.
conclusionTolvaptan can decrease body weight, increase serum sodium level, and ameliorate some of the congestion symptoms in patients with acute heart failure, which may help avoid the overdose of loop diuretics, especially in patients with renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.